Previously, we have shown, both in humans and monkeys, that the latencies of exogenously generated saccades decrease with an increase in the number of response alternatives (Lawrence et al. in J Vis 8:26, 1-7, 2008). Because this pattern of latencies was in the direction opposite that predicted by Hick (Q J Exp Psychol 4:11-26, 1952), we termed the effect an "anti-Hick's" effect. In contrast, previous research has shown that reach latencies increase with an increase in response alternatives (e.g., Wright et al. in Exp Brain Res 179:475-496, 2007). Given that there are known interactions between the saccade and reach systems, we examined whether the direction of the relationship between latencies and response alternatives differed when saccades and reaches are concomitantly executed. Interestingly, we found that the pattern of latencies nevertheless persisted in a visually guided saccade and reach task. These results place an important constraint on the anti-Hick's effect, suggesting not only that the effect is localized within the saccade system, but also that it is localized in the saccade system at a level in which saccade and reach signals do not interact.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00221-009-1804-7 | DOI Listing |
Bull Cancer
March 2025
Oncologie médicale, Institut Curie, Paris, France.
Patients who develop Ewing sarcoma with extra-pulmonary metastasis have a poor prognosis. A recent French protocol, CombinaiR3, was set up to evaluate the efficacy of induction chemotherapy followed by high-dose chemotherapy and metronomic maintenance treatment. It is now closed for inclusions and while waiting for the results, we propose a French consensus guideline for the management of patients diagnosed with Ewing sarcoma with extra-pulmonary dissemination.
View Article and Find Full Text PDFBest Pract Res Clin Haematol
December 2024
Department of Medicine, Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized treatment options for B-cell Non-Hodgkin Lymphoma (NHL). CD19-targeting CAR-T cell therapy is approved for treatment in Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CAR-T cells demonstrate robust and durable responses even in heavily pretreated patients.
View Article and Find Full Text PDFJ Genet Eng Biotechnol
March 2025
Centre for Bioinformatics, M.D. University, Rohtak, Haryana, India. Electronic address:
The emergence of multidrug resistanceagainst several antifungal drugs and the absence of alternate therapy limits the treatment choices leading to the spread of Candida auris infections, especially inimmunocompromised patients. This work aims to construct the multi-epitope vaccine using an immuno-informatics approachdue to the lack of efficient treatments for C. auris.
View Article and Find Full Text PDFJ Immunother Cancer
March 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes.
View Article and Find Full Text PDFInt J Pharm
March 2025
Bioinformatics Center of AMMS, Beijing, People's Republic of China. Electronic address:
Traditional mRNA vaccine formulation loaded by lipid nanoparticle (mRNA-LNP) has several shortcomings in clinical application, including the need for cryopreservation, discomfort associated with intramuscular injections, and the risk of liver aggregation. Dissolvable microneedles (DMNs), as a novel transdermal drug delivery platform, can overcome the skin barrier to deliver drugs directly into the skin in a minimally invasive manner. However, mRNA-LNP is unstable and easily degraded during the solidification of DMN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!